367 related articles for article (PubMed ID: 33502484)
1. Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
Wu H; Shi J; Luo Y; Tan Y; Zhang M; Lai X; Yu J; Liu L; Fu H; Huang H; Zhao Y
JAMA Netw Open; 2021 Jan; 4(1):e2034750. PubMed ID: 33502484
[TBL] [Abstract][Full Text] [Related]
2. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
Front Immunol; 2021; 12():673636. PubMed ID: 34276662
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N
Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
[TBL] [Abstract][Full Text] [Related]
6. Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement.
Kaurinovic M; Delli K; Jonk AE; Biswana A; Hazenberg CLE; Choi G; de Groot MR; Morsink LM; Vissink A; Bellido M
Clin Oral Investig; 2022 May; 26(5):4209-4216. PubMed ID: 35169886
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease.
Modi B; Hernandez-Henderson M; Yang D; Klein J; Dadwal S; Kopp E; Huelsman K; Mokhtari S; Ali H; Malki MMA; Spielberger R; Salhotra A; Zain J; Cotliar J; Parker P; Forman S; Nakamura R
Biol Blood Marrow Transplant; 2019 Feb; 25(2):265-269. PubMed ID: 30201397
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.
Zhang MY; Zhao P; Zhang Y; Wang JS
PLoS One; 2022; 17(7):e0271979. PubMed ID: 35905125
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.
Abedin S; McKenna E; Chhabra S; Pasquini M; Shah NN; Jerkins J; Baim A; Runaas L; Longo W; Drobyski W; Hari PN; Hamadani M
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1689-1694. PubMed ID: 30965140
[TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib Treatment of Steroid-Refractory Graft-versus-Host Disease in Children: A Case Series and Review of the Literature.
Yan WL; Zhao FY; Gu ME; Liu N; Guo XP; Xu XJ
Paediatr Drugs; 2023 Sep; 25(5):577-584. PubMed ID: 37284944
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges.
Redondo S; Esquirol A; Novelli S; Caballero AC; Garrido A; Oñate G; López J; Moreno C; Saavedra SD; Granell M; Briones J; Sierra J; Martino R; García-Cadenas I
Transplant Cell Ther; 2022 Jan; 28(1):43.e1-43.e5. PubMed ID: 34757054
[TBL] [Abstract][Full Text] [Related]
12. Effect of Ruxolitinib on Lung Function after Allogeneic Stem Cell Transplantation.
Bondeelle L; Chevret S; Hurabielle C; Samy L; Goletto T; Costantini A; Sicre de Fontbrune F; Michonneau D; Socié G; Tazi A; Bouaziz JD; Bergeron A
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2115-2120. PubMed ID: 32738501
[TBL] [Abstract][Full Text] [Related]
13. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC.
Laisne L; Neven B; Dalle JH; Galambrun C; Esvan M; Renard C; Rialland F; Sirvent A; Gandemer V;
Pediatr Blood Cancer; 2020 Sep; 67(9):e28233. PubMed ID: 32614145
[TBL] [Abstract][Full Text] [Related]
14. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.
Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B
J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Follow-Up of Ruxolitinib in the Treatment of Steroid-Refractory Chronic Graft-versus-Host Disease.
Ferreira AM; Szor RS; Molla VC; Seiwald MC; de Moraes PA; da Fonseca ARBM; Xavier EM; Serpa MG; Tucunduva L; Novis Y; Arrais-Rodrigues C
Transplant Cell Ther; 2021 Sep; 27(9):777.e1-777.e6. PubMed ID: 34118469
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients.
Wei C; Zhang X; Liang D; Yang J; Du J; Yue C; Deng L
Drug Des Devel Ther; 2021; 15():4875-4883. PubMed ID: 34880598
[TBL] [Abstract][Full Text] [Related]
17. The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study.
Yang W; Zhu G; Qin M; Li Z; Wang B; Yang J; Wang T
Drug Des Devel Ther; 2021; 15():743-752. PubMed ID: 33654380
[TBL] [Abstract][Full Text] [Related]
18. ECP versus ruxolitinib in steroid-refractory chronic GVHD - a retrospective study by the EBMT transplant complications working party.
Penack O; Peczynski C; Boreland W; Lemaitre J; Reinhardt HC; Afanasyeva K; Avenoso D; Holderried TAW; Kornblit BT; Gavriilaki E; Martinez C; Chiusolo P; Mico MC; Dagunet E; Wichert S; Ozdogu H; Piekarska A; Kinsella F; Basak GW; Schoemans H; Koenecke C; Moiseev I; Peric Z
Bone Marrow Transplant; 2024 Mar; 59(3):380-386. PubMed ID: 38184740
[TBL] [Abstract][Full Text] [Related]
19. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
[TBL] [Abstract][Full Text] [Related]
20. Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience.
Xue E; Lorentino F; Pavesi F; Assanelli A; Peccatori J; Bernardi M; Corti C; Ciceri F; Lupo Stanghellini MT
Leuk Res; 2021 Oct; 109():106642. PubMed ID: 34157510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]